Bay Area biotech Culture Biosciences reels in $5.5M in funding

Digital is expected to account for just under half of APAC's ad spend this year (Image metamorworks / iStockPhoto)
Culture's goal is to make fermentation a digital experience that will allow scientists to conduct experiments from their computers much as a software engineer tests and compiles code. (metamorworks/iStockPhoto)

Culture Biosciences, a Bay Area biotech focused on biomanufacturing as a service, reeled in $5.5 million in funding that will be used to expand its operations.

The funding was led by Section 32. Additional participants in the financing include Refactor Capital and Verily.

Culture said the money will target expansion of its digital biomanufacturing platform and development of additional bioreactor facilities.

FREE DAILY NEWSLETTER

Like this story? Subscribe to FierceBiotech!

Biopharma is a fast-growing world where big ideas come along every day. Our subscribers rely on FierceBiotech as their must-read source for the latest news, analysis and data in the world of biotech and pharma R&D. Sign up today to get biotech news and updates delivered to your inbox and read on the go.

“Biotechnology is poised to transform industries ranging from healthcare to food, but it is limited by arduous and time-consuming approaches to fermentation, the key process involved in manufacturing bio-based products at scale,” Will Patrick, Culture’s chief executive, said in a statement.

Patrick added that Culture's goal is to make fermentation a digital experience that will allow scientists to conduct experiments from their computers much as a software engineer tests and compiles code.

The company’s platform, which is currently being used by leading biotech companies as part of an effort to optimize R&D, integrates bioreactors, cloud monitoring and remote operations.

Read more on

Suggested Articles

Scott Gottlieb has slipped right back into his old ways, becoming "special partner" at his old life science VC firm New Enterprise Associates.

Novartis, Otsuka, Pfizer and Sanofi will use technology from Verily’s Project Baseline to carry out clinical studies in various disease areas.

Biotech-CRO hybrid Evotec is continuing its buying and collaborating strategy with its acquisition of U.S. biologics company Just Biotherapeutics.